Tuspetinib (HM43239) for Myeloid Tumors
Oral, Potent Myeloid Kinase Inhibitor (MKI)
Tuspetinib (HM43239) is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
View Candidate
Posters & Presentations
Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.
View Posters & Presentations